Target intelligence / Profile preview

Ferriprotoporphyrin IX (Free heme) (FP-IX)

Target
FP-IX
Molecular classification
Metalloporphyrin, Metabolic byproduct, Non-protein target
01

Overview

Free heme, specifically ferriprotoporphyrin IX (FP-IX), is a toxic byproduct generated during the intraerythrocytic stage of the Plasmodium falciparum life cycle (Sullivan et al., 1996). The parasite digests host hemoglobin within its acidic digestive vacuole to obtain essential amino acids, releasing large quantities of free heme. Because free heme is redox-active and can damage parasite membranes and proteins, the parasite detoxifies it by sequestering it into an insoluble crystalline form called hemozoin, or malaria pigment (Egan, 2008). Many antimalarial drugs, most notably the quinolines like chloroquine, act by binding to free heme or the growing faces of hemozoin crystals, thereby preventing further crystallization (Combrinck et al., 2013). This leads to the accumulation of toxic free heme within the digestive vacuole, ultimately causing parasite death through oxidative stress and membrane disruption. This pathway remains a cornerstone of antimalarial therapy, although resistance mechanisms such as mutations in the PfCRT transporter pose significant therapeutic challenges (Haldar et al., 2018).

Other names
HemeHematinMalaria pigment precursorProtoporphyrin IX iron(III) complexFerriheme
02

Mechanism of action

Inhibition of heme biocrystallization into hemozoin, leading to the accumulation of toxic free heme which causes oxidative damage and membrane lysis within the parasite digestive vacuole.

03

Biological functions

Hemoglobin catabolismOxidative stress inductionBiocrystallization
04

Disease associations

MalariaInfection
05

Safety considerations

Drug resistance mediated by PfCRT mutationsHeme-induced oxidative stressTherapeutic challenges due to parasite sequestration in deep tissues
06

Interacting drugs

Chloroquine

7 more in the full profile.

07

Biomarkers

Hemozoin levelsParasite clearance rateIntraerythrocytic heme concentrations

Beyond the preview

Go deeper on Ferriprotoporphyrin IX (Free heme) (FP-IX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ferriprotoporphyrin IX (Free heme) (FP-IX).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call